Breast Cancer Steering Committee
The NCI Breast Cancer Steering Committee (BCSC) was established in September 2008.
The BCSC functions to coordinate an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in breast cancer clinical research by addressing the design and prioritization of phase 3 and large phase 2 trials in breast cancer.
BOLD (Breast Oncology Local Disease): Mark Basik, M.D. and Rich Zellars, M.D., Co-chairs
- How to Access the BOLD TF CDEs
- NCI BOLD Task Force General CDEs
- NCI BOLD Task Force Preoperative CDEs
- NCI BOLD Task Force Surgical CDEs
- NCI BOLD Task Force Radiation CDEs
- NCI BOLD Task Force Imaging CDEs
Clinical Trial Planning Meetings (CTPM)
- Life Style Intervention for Improving Disease-Free Survival in Early Stage Invasive Breast Cancer CTPM - February 2014
- Next Generation Trials for Estrogen Receptor (ER) + Breast Cancer CTPM – May 2012
- Next Generation Trials for HER2 + Breast Cancer CTPM - May 2011
Workshops and Meetings
The following are clinical trials that were approved at the concept stage by the Steering Committee.
|Trial ID||NCT ID||Trial Title|
|NCIC CTG-MA.32||NCT01101438||A Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer|
|SWOG-S1007||NCT01272037||A Phase III, Randomized Clinical Trial of Standard Adjuvant EndocrineTherapy +/- Chemotherapy in Patients with 1-9 Positive Nodes, Hormone-responsive and HER2-negative Breast Cancer according to Recurrence Score (RS)|
|ECOG-E2108||NCT01242800||A Randomized Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer|
|RTOG-1005||NCT01349322||A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation with Conventional Fractionation plus Sequential Boost for Early-Stage Breast Cancer|
|NSABP B-49||NCT01547741||A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer|
|RTOG-1119||NCT01622868||Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer – A Collaborative Study of RTOG and KROG|
|NSABP B-51/RTOG-1304||NCT01872975||A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy|
|SWOG-1207||NCT01674140||A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer|
|NSABP B-52||NCT02003209||A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation|
|ALLIANCE-A011202||NCT01901094||A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy|
|ECOG-ACRIN E2112||NCT02115282||A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer|
CCCT Contact: Jennifer Hayes, Ph.D.